A. Bello

发表

The effects of ketoconazole and rifampin on the single-dose pharmacokinetics of crizotinib in healthy subjects

Weiwei Tan, Huiping Xu, M. O’Gorman, 2015, European Journal of Clinical Pharmacology.

Dosing Celecoxib in Pediatric Patients With Juvenile Rheumatoid Arthritis

M. Hutmacher, A. Bello, S. Krishnaswami, 2012, Journal of clinical pharmacology.

Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma.

J. Burke, R. Figlin, R. Motzer, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Single-Dose Pharmacokinetics of Milvexian in Participants with Mild or Moderate Hepatic Impairment Compared with Healthy Participants

A. Bello, Liping Zhang, Zhaoqing Wang, 2022, Clinical Pharmacokinetics.

Clinical Pharmacology Considerations for the Development of Immune Checkpoint Inhibitors

A. Bello, S. Srivastava, B. Schmidt, 2017, Journal of clinical pharmacology.

Population pharmacokinetics analysis of nivolumab in Asian and non-Asian patients with gastric and gastro-esophageal junction cancers

A. Bello, M. Osawa, A. Roy, 2019, Cancer Chemotherapy and Pharmacology.

Single-Dose Pharmacokinetics of Milvexian in Participants with Normal Renal Function and Participants with Moderate or Severe Renal Impairment

A. Bello, Liping Zhang, Zhaoqing Wang, 2022, Clinical Pharmacokinetics.

Population Pharmacokinetics and Exposure — Safety Analyses of Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

E. Ludwig, A. Bello, J. Passarell, 2018, Journal of clinical pharmacology.

Estrogen suppression in premenopausal women following 8 weeks of treatment with exemestane and triptorelin versus triptorelin alone

P. Buchan, A. Bello, E. Salle, 2009, Breast Cancer Research and Treatment.

Pharmacokinetics and Pharmacodynamics of Figitumumab, a Monoclonal Antibody Targeting the Insulin‐Like Growth Factor 1 Receptor, in Healthy Participants

D. Yin, A. Bello, C. Alvey, 2013, Journal of clinical pharmacology.

Multiple-Dose Safety and Pharmacokinetics of Oral Garenoxacin in Healthy Subjects

D. Gajjar, D. Grasela, A. Bello, 2003, Antimicrobial Agents and Chemotherapy.

Population Pharmacokinetics and Pharmacodynamics of Garenoxacin in Patients with Community-Acquired Respiratory Tract Infections therapeutic relationships for

E. Ludwig, D. Gajjar, D. Grasela, 2004 .

Model-based evaluation of the efficacy and safety of nivolumab once every 4 weeks across multiple tumor types.

V. Ivaturi, V. Goodman, J. Gobburu, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Model‐Based Population Pharmacokinetic Analysis of Nivolumab in Chinese Patients With Previously Treated Advanced Solid Tumors, Including Non–Small Cell Lung Cancer

Jason Zhang, A. Bello, Junliang Cai, 2019, Journal of clinical pharmacology.

The Clinical Pharmacology of Elotuzumab

Michael D. Robbins, R. Dodge, A. Bello, 2018, Clinical Pharmacokinetics.

Preventive effects of perioperative parecoxib on post-discectomy pain.

M. Eikermann, J. Peters, A. Bello, 2008, British journal of anaesthesia.

Model-based assessment of benefit-risk profile of nivolumab (NIVO) flat dosing schedules (Q2W and Q4W) across multiple tumor types.

V. Ivaturi, J. Gobburu, X. Zhao, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Pharmacokinetics (PK) of crizotinib (PF-02341066) in patients with advanced non-small cell lung cancer (NSCLC) and other solid tumors.

K. Wilner, A. Bello, C. Li, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

An Integrated Assessment of the Effects of Immunogenicity on the Pharmacokinetics, Safety, and Efficacy of Elotuzumab

L. Gibiansky, R. Dodge, A. Bello, 2017, The AAPS Journal.

Best practices for the use of itraconazole as a replacement for ketoconazole in drug–drug interaction studies

E. O'Mara, M. Rogge, D. Heald, 2016, Journal of clinical pharmacology.

Nivolumab Exposure–Response Analyses of Efficacy and Safety in Previously Treated Squamous or Nonsquamous Non–Small Cell Lung Cancer

S. Agrawal, A. Bello, B. Lestini, 2017, Clinical Cancer Research.

Phase II trial of continuous once‐daily dosing of sunitinib as first‐line treatment in patients with metastatic renal cell carcinoma

C. Barrios, Se-Hoon Lee, Jin-Hwang Liu, 2012, Cancer.

Linking Tumor Growth Dynamics to Survival in Ipilimumab‐Treated Patients With Advanced Melanoma Using Mixture Tumor Growth Dynamic Modeling

S. Suryawanshi, A. Bello, Xiaoning Wang, 2019, CPT: pharmacometrics & systems pharmacology.

Intravenous Parecoxib Rapidly Leads to COX‐2 Inhibitory Concentration of Valdecoxib in the Central Nervous System

A. Johnston, A. Bello, R. Cheung, 2008, Clinical pharmacology and therapeutics.

Effects of Renal Function on Crizotinib Pharmacokinetics: Dose Recommendations for Patients with ALK-Positive Non-Small Cell Lung Cancer

T. R. Johnson, Weiwei Tan, S. Yamazaki, 2017, Clinical Drug Investigation.

Evaluation of crizotinib absolute bioavailability, the bioequivalence of three oral formulations, and the effect of food on crizotinib pharmacokinetics in healthy subjects

Weiwei Tan, Huiping Xu, M. O’Gorman, 2015, Journal of clinical pharmacology.

A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors.

Suzanne F. Jones, L. Tye, H. Burris, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Assessment of hyperprogression versus the natural course of disease development with nivolumab with or without ipilimumab versus placebo in phase III, randomized, controlled trials

T. Owonikoko, Han Chang, Yoon-Koo Kang, 2022, Journal for ImmunoTherapy of Cancer.

Polymeric Nanoparticles for Increased Oral Bioavailability and Rapid Absorption Using Celecoxib as a Model of a Low-Solubility, High-Permeability Drug

M. Morgen, R. Steenwyk, A. Bello, 2011, Pharmaceutical Research.

Concentrations of the des-F(6)-quinolone garenoxacin in plasma and joint cartilage of immature rats

R. Stahlmann, A. Bello, M. Kastner, 2004, Archives of Toxicology.

Metabolism, excretion and pharmacokinetics of [14C]crizotinib following oral administration to healthy subjects

G. S. Walker, T. R. Johnson, J. Christensen, 2015, Xenobiotica; the fate of foreign compounds in biological systems.

Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer

C. Garbe, G. Long, X. Zhao, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Assessment of nivolumab benefit–risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors

X. Zhao, S. Agrawal, S. Suryawanshi, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Population Pharmacokinetics and Pharmacodynamics of Garenoxacin in Patients with Community-Acquired Respiratory Tract Infections

E. Ludwig, D. Gajjar, D. Grasela, 2004, Antimicrobial Agents and Chemotherapy.

Effect of a High‐Fat Meal on the Pharmacokinetics of the Des‐F(6)‐Quinolone BMS‐284756

D. Gajjar, D. Grasela, A. Bello, 2002, Pharmacotherapy.

Tolerability/safety of sunitinib (SU) on schedule 2/1 in combination with capecitabine (C) in patients (pts) with advanced solid tumors (STs): A phase I dose-finding study

Suzanne F. Jones, L. Tye, H. Burris, 2008 .

Development of a prognostic composite cytokine signature based on the correlation with nivolumab clearance: translational PK/PD analysis in patients with renal cell carcinoma

A. Bello, Joshua Zhang, Rui Wang, 2019, Journal of Immunotherapy for Cancer.

A Machine‐Learning Approach to Identify a Prognostic Cytokine Signature That Is Associated With Nivolumab Clearance in Patients With Advanced Melanoma

A. Saci, Xiaozhong Qian, R. Moss, 2019, Clinical pharmacology and therapeutics.

Nivolumab Clearance Is Stationary in Patients With Resected Melanoma on Adjuvant Therapy: Implications of Disease Status on Time‐Varying Clearance

A. Bello, P. Statkevich, G. Bajaj, 2019, Clinical pharmacology and therapeutics.

Evaluation of Proton Pump Inhibitor Esomeprazole on Crizotinib Pharmacokinetics in Healthy Participants

Weiwei Tan, Kyle T. Matschke, Huiping Xu, 2021, Clinical pharmacology in drug development.

Pharmacokinetics (PK) of PF-562271, a focal adhesion kinase (FAK) inhibitor, and its effect on CYP3A in patients with advanced nonhematologic malignancies.

S. Shreeve, K. Pierce, D. Yin, 2010 .

Model-based pharmacokinetic analysis of elotuzumab in patients with relapsed/refractory multiple myeloma

L. Gibiansky, A. Bello, C. Passey, 2016, Journal of Pharmacokinetics and Pharmacodynamics.

Clinical Implications of the Pharmacokinetics of Crizotinib in Populations of Patients with Non–Small Cell Lung Cancer

Weiwei Tan, K. Wilner, A. Bello, 2016, Clinical Cancer Research.

Concentrations of garenoxacin in plasma, bronchial mucosa, alveolar macrophages and epithelial lining fluid following a single oral 600 mg dose in healthy adult subjects.

D. Gajjar, A. Bello, D. Honeybourne, 2003, The Journal of antimicrobial chemotherapy.

Effects of the Des-F(6)-Quinolone Garenoxacin (BMS-284756), in Comparison to Those of Ciprofloxacin and Ofloxacin, on Joint Cartilage in Immature Rats

M. Shakibaei, R. Stahlmann, A. Bello, 2002, Antimicrobial Agents and Chemotherapy.

Abstract CT101: A model-based exposure-response (E-R) assessment of a nivolumab (NIVO) 4-weekly (Q4W) dosing schedule across multiple tumor types

V. Ivaturi, V. Goodman, J. Gobburu, 2017 .

Evaluation of Therapeutics for Severely Debilitating or Life‐Threatening Diseases or Conditions: Defining Scope to Enable Global Guidance Development

A. Bello, James Hartke, Mazin Derzi, 2020, Clinical pharmacology and therapeutics.

Assessment of nivolumab (Nivo) benefit-risk profile from a 240-mg flat dose versus a 3-mg/kg dosing regimen in patients (Pts) with solid tumors

X. Zhao, S. Agrawal, S. Suryawanshi, 2016 .

Characterization of the Penetration of Garenoxacin into the Breast Milk of Lactating Women

D. Gajjar, D. Nicolau, A. Bello, 2004, Journal of clinical pharmacology.

Polymeric Nanoparticles for Increased Oral Bioavailability and Rapid Absorption Using Celecoxib as a Model of a Low-Solubility, High-Permeability Drug

M. Morgen, R. Steenwyk, A. Bello, 2011, Pharmaceutical Research.

Calcium antagonist properties of the bisbenzylisoquinoline alkaloid cycleanine

A. Bello, L. Galán, C. Rodríguez, 1998, Fundamental & clinical pharmacology.

The effects of ketoconazole and rifampin on the single-dose pharmacokinetics of crizotinib in healthy subjects

Weiwei Tan, Huiping Xu, M. O’Gorman, 2015, European Journal of Clinical Pharmacology.

Nivolumab Exposure–Response Analyses of Efficacy and Safety in Previously Treated Squamous or Nonsquamous Non–Small Cell Lung Cancer

S. Agrawal, A. Bello, B. Lestini, 2017, Clinical Cancer Research.

Article Type: Original Title: Assessment of nivolumab benefit-risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors

X. Zhao, S. Agrawal, S. Suryawanshi, 2017 .